All In Biotech

Free tool

FAERS Monitor: Scemblix

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215358 or its brand name (Scemblix, Asciminib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

3,492

Serious

2,282

65% of reports

Hospitalization

644

Death reported

390

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue265
  • death201
  • nausea185
  • drug ineffective179
  • thrombocytopenia171
  • drug intolerance141
  • headache141
  • diarrhoea138
  • rash110
  • pleural effusion109
  • hypertension106
  • arthralgia104
  • off label use104
  • dyspnoea96
  • cytopenia95

Reports by year received

View as table
YearReports
20171
20183
201914
202022
202133
2022412
2023556
2024716
2025934
2026801

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,667 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cytopeniaSignal9547.138.64,209
pleural effusionSignal10910.89.0961
thrombocytopeniaSignal1719.28.01,250
drug intoleranceSignal1418.87.5970
hypertensionSignal1063.02.5142
fatigueSignal2652.11.8147
rash1101.51.319
arthralgia1041.51.218
nausea1851.41.222
death2011.41.224
headache1411.41.213
diarrhoea1381.31.19
dyspnoea961.00.80
drug ineffective1790.80.78
off label use1040.70.612

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.